Literature DB >> 3038305

DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone.

E Sariban, K W Kohn, C Zlotogorski, G Laurent, M D'Incalci, R Day, B H Smith, P L Kornblith, L C Erickson.   

Abstract

Cell strains derived by culture of malignant glioma (astrocytoma grade III-IV) surgical specimens were tested for the production of DNA interstrand cross-links (ISC) and DNA-protein cross-links following treatment in vitro with 1-(2-chloroethyl)-1-nitrosourea, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU, carmustine), 1-(2-chloroethyl)-3-(2,6-dioxo-1-piperidyl)-1-nitrosourea (PCNU), cis-dichlorodiammineplatinum(II) (cisplatin), and 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (diaziquone). ISC and DNA-protein crosslinks were measured by means of the DNA alkaline elution technique. Large differences among the cell strains were observed in DNA cross-linking responses to individual agents. The DNA responses to the chloroethylnitrosoureas, cisplatin, and diaziquone were largely independent of each other, except for a weak correlation between ISC responses to chloroethylnitrosoureas were distributed bimodally, in accord with a phenotypic distinction between Mer+ and Mer- cells. ISC responses to cisplatin and diaziquone showed significant variation among cell strains, but the distributions were not bimodal. The results demonstrate the existence of diverse DNA cross-linking response patterns among cell strains from different tumors of a given histological type.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038305

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Management of primary malignant brain tumours.

Authors:  I R Whittle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

2.  Selective cytoplasmic and membrane changes induced by cisplatinum.

Authors:  M A Oberc-Greenwood; B H Smith; C Cooke; C Pepin; P L Kornblith
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

Review 3.  High dose chemotherapy for the treatment of malignant brain tumors.

Authors:  S H Petersdorf; R B Livingston
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 4.  Drug resistance in brain tumors.

Authors:  L G Feun; N Savaraj; H J Landy
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 5.  The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.

Authors:  A Gutenberg; C B Lumenta; W E K Braunsdorf; M Sabel; H M Mehdorn; M Westphal; A Giese
Journal:  J Neurooncol       Date:  2013-03-28       Impact factor: 4.130

Review 6.  Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Authors:  Jann N Sarkaria; Gaspar J Kitange; C David James; Ruth Plummer; Hilary Calvert; Michael Weller; Wolfgang Wick
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

7.  Potential of O6-methylguanine or O6-benzylguanine in the enhancement of chloroethylnitrosourea cytotoxicity on brain tumours.

Authors:  K Mineura; I Izumi; K Watanabe; M Kowada; K Kohda; M Ikenaga
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines.

Authors:  J F Costello; B W Futscher; R A Kroes; R O Pieper
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

9.  DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase.

Authors:  J Beith; J Hartley; J Darling; R Souhami
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.